CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Coverage criteria for cysteamine therapy for nephropathic cystinosis

This policy governs prior authorization and continuation criteria for prescription cysteamine therapy to treat nephropathic cystinosis for members of Neighborhood Health Plan of Rhode Island.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyCoverage criteria for cysteamine therapy for nephropathic cystinosis

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionRequest initial prior authorization for 6 months when diagnosis is confirmed, specialist involvement is documented, monitoring is planned, no Procysbi co‑use, and dose ≤ 1.95 g/m2/day.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthsinitial auth

12 monthscontinuation auth

1.95 g/m2/daymax dose

<0.2 nmol/gWBC cystine ref

Coverage Criteria for Cysteamine Therapy

Initial Authorization Criteria

Initial therapy: Covered when ALL of the following are met

Initial criteria: Member has a diagnosis of nephropathic cystinosis.

Diagnosis confirmation: Diagnosis is confirmed by ONE of: increased leukocyte cystine concentration (normal: <0.2 nmol halfcystine/g protein) OR genetic testing demonstrating pathogenic/pathologic variant(s) in the cystinosin (lysosomal cystine transporter) gene.<0.2 nmol halfcystine/g protein (normal leukocyte cystine)

Prescriber: Prescribed by or in consultation with a specialist experienced in treating nephropathic cystinosis (e.g., endocrinologist, nephrologist, or urologist).

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyCoverage criteria for cysteamine therapy for nephropathic cystinosis

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionRequest initial prior authorization for 6 months when diagnosis is confirmed, specialist involvement is documented, monitoring is planned, no Procysbi co‑use, and dose ≤ 1.95 g/m2/day.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Authorization Durations, Documentation, and Actionable Rules

Prior Authorization

Initial authorization: 6 months (prior authorization required)

Initial prior authorization may be granted for 6 months when all listed criteria are met, including confirmed diagnosis, specialist prescribing or consultation, monitoring plan, avoidance of Procysbi, and dose within the maximum limit.

Diagnosis of nephropathic cystinosis required
Diagnosis confirmed by increased leukocyte cystine concentration (<0.2 nmol halfcystine/g protein) or genetic testing
Prescribed by or in consultation with a specialist experienced in nephropathic cystinosis (e.g., endocrinologist, nephrologist, urologist)
Monitoring plan in place (WBC cystine levels or plasma cysteamine concentration)
Not to be used with Procysbi (cysteamine bitartrate)
Dose must not exceed 1.95 g/m2 per day

Prior Authorization

Continuation authorization: 12 months (response required)

Continuation prior authorization may be granted for 12 months for members demonstrating a positive response to therapy as shown by improvement, stabilization, or slowing of disease progression in leukocyte cystine concentration.

Documented positive response in leukocyte cystine concentration since starting treatment

Step Therapy

Step therapy

No step therapy requirements are specified for cysteamine therapy in this policy.

Documentation Required

Required documentation to support authorization

Required documentation must include confirmation of nephropathic cystinosis by either elevated leukocyte cystine concentration or genetic testing, plus evidence of specialist involvement and a monitoring plan with results.

Confirmation by increased leukocyte cystine concentration (normal: <0.2 nmol halfcystine/g protein) OR genetic testing for pathogenic Cystinosin variants
Prescribing clinician specialty or consultation note from a specialist experienced in nephropathic cystinosis
Monitoring plan and results (WBC cystine levels or plasma cysteamine concentration)

Denial Risk

Triggers for denial

Requests may be denied if they exceed the policy’s maximum dose, request use in combination with Procysbi, or lack a confirmed diagnosis of nephropathic cystinosis.

Dose exceeds 1.95 g/m2 per day
Concurrent use with Procysbi (cysteamine bitartrate)
No confirmation of diagnosis by leukocyte cystine concentration or genetic testing

Background

Nephropathic cystinosis is a genetic lysosomal storage disorder characterized by pathogenic variants in the cystinosin (CTNS) gene that result in accumulation of cystine within cells. Clinical diagnosis is established by either an increased leukocyte cystine concentration (reference: <0.2 nmol halfcystine/g protein as normal) or by genetic testing demonstrating pathologic CTNS variants. Management includes cysteamine therapy to reduce intracellular cystine; treatment should be prescribed or managed by a specialist experienced in nephropathic cystinosis (for example, an endocrinologist, nephrologist, or urologist) with monitoring of effectiveness using leukocyte (WBC) cystine levels or plasma cysteamine concentrations.

OpenPayer

Coverage criteria for cysteamine therapy for nephropathic cystinosis

Coverage Criteria for Cysteamine Therapy

Key Clinical Thresholds and Dosing Limits

Authorization Durations, Documentation, and Actionable Rules

Definitions and Diagnostic Confirmation

Background